Literature DB >> 35522323

225Ac-DOTATATE therapy in a case of metastatic pheochromocytoma.

Dengsai Peng1,2,3, Hanxiang Liu1,2,3, Ling Huang4, Jianpeng Cao1,2,3, Yue Chen5,6,7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35522323     DOI： 10.1007/s00259-022-05826-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   10.057


× No keyword cloud information.
  5 in total

1.  Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

Authors:  Jonathan Strosberg; Ghassan El-Haddad; Edward Wolin; Andrew Hendifar; James Yao; Beth Chasen; Erik Mittra; Pamela L Kunz; Matthew H Kulke; Heather Jacene; David Bushnell; Thomas M O'Dorisio; Richard P Baum; Harshad R Kulkarni; Martyn Caplin; Rachida Lebtahi; Timothy Hobday; Ebrahim Delpassand; Eric Van Cutsem; Al Benson; Rajaventhan Srirajaskanthan; Marianne Pavel; Jaime Mora; Jordan Berlin; Enrique Grande; Nicholas Reed; Ettore Seregni; Kjell Öberg; Maribel Lopera Sierra; Paola Santoro; Thomas Thevenet; Jack L Erion; Philippe Ruszniewski; Dik Kwekkeboom; Eric Krenning
Journal:  N Engl J Med       Date:  2017-01-12       Impact factor: 91.245

Review 2.  Neuroendocrine Tumor Therapy: 177Lu-DOTATATE.

Authors:  Erik S Mittra
Journal:  AJR Am J Roentgenol       Date:  2018-06-27       Impact factor: 3.959

3.  Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine.

Authors:  S D Averbuch; C S Steakley; R C Young; E P Gelmann; D S Goldstein; R Stull; H R Keiser
Journal:  Ann Intern Med       Date:  1988-08-15       Impact factor: 25.391

4.  Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety.

Authors:  Sanjana Ballal; Madhav Prasad Yadav; Chandrasekhar Bal; Ranjit Kumar Sahoo; Madhavi Tripathi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-10       Impact factor: 9.236

5.  Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate.

Authors:  D J Kwekkeboom; W H Bakker; B L Kam; J J M Teunissen; P P M Kooij; W W de Herder; R A Feelders; C H J van Eijck; M de Jong; A Srinivasan; J L Erion; E P Krenning
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-01-09       Impact factor: 9.236
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.